Liposomal GM1 - InnoMedica
Alternative Names: Liposomal GM1; Liposomal monosialotetrahexosylganglioside; TALINEUREN®; TLGM-1; TLSG-1Latest Information Update: 13 Jun 2024
At a glance
- Originator InnoMedica
- Class Antiparkinsonians; Gangliosides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Parkinson's disease
Most Recent Events
- 29 May 2024 InnoMedica Schweiz plans a phase II trial in Parkinson disease (Adjunctive treatment) in Switzerland (IV) in August 2024 (NCT06431971)
- 07 Dec 2021 Phase-I clinical trials in Parkinson's disease in Switzerland (IV) (NCT04976127)
- 28 Aug 2021 No recent reports of development identified for preclinical development in Parkinson's-disease in Switzerland (Liposomal)